TABLE II.
Crizotinib treatment patterns
| All Patients (n=212) | Setting of Crizotinib Initiation (n=210)a | |||
|---|---|---|---|---|
|
| ||||
| First-Line (n=137) | Second- or Later-Line (n=73) | P value | ||
| Time (days) from initial diagnosisb to crizotinib initiation | ||||
| Mean (SD) | 85.4 (132.7) | 39.6 (64.5) | 169.1 (178.0) | <0.0001 |
| Median | 26 | 20 | 91 | |
| Range (minimum, maximum) | (0, 720) | (0, 420) | (0, 720) | |
| Initial crizotinib total daily dose prescribed, n (%) | 0.0452 | |||
| 200 mg b.i.d. | 32 (15.1) | 22 (16.2) | 8 (11.0) | |
| 250 mg b.i.d. | 169 (79.7) | 111 (81.6) | 58 (79.5) | |
| 200 mg q.d. | 8 (3.8) | 3 (2.2) | 4 (5.5) | |
| 250 mg q.d. | 3 (1.4) | — | 3 (4.1) | |
| Crizotinib dose changes, n (%) | ||||
| Had ≥1 dose reduction | 15 (7.1) | 7 (5.1) | 8 (11.0) | 0.1207 |
| Had ≥1 dose escalation | 6 (2.8) | 2 (1.5) | 4 (5.5) | 0.0980 |
| Had no dose changes | 190 (89.6) | 126 (92.6) | 61 (83.6) | 0.0413 |
| Unknown | 1 (0.5) | 2 (1.5) | — | 0.4329 |
| Duration (months) of crizotinib treatment, from initiation to last observed dose, median | 8.7 | 9.0 | 8.5 | 0.1008 |
| Reason(s) for final discontinuation of crizotinib, n (%) | ||||
| Death | 2 (3.1) | 1 (2.4) | 1 (4.3) | 0.6737 |
| Disease progression following initial response | 126 (59.4) | 90 (66.2) | 36 (49.3) | 0.0175 |
| Disease progression following no initial response | 29 (13.7) | 14 (10.3) | 14 (19.2) | 0.0722 |
| Treatment-related toxicity or side effects | 10 (4.7) | 2 (1.5) | 8 (11.0) | 0.0022 |
| Patient request | 41 (19.3) | 25 (18.4) | 15 (20.5) | 0.7044 |
| Other reason(s) | 8 (3.8) | 4 (2.9) | 4 (5.5) | 0.3619 |
| Unknown | 6 (2.8) | 3 (2.2) | 2 (2.7) | 0.7432 |
| Other treatments received after crizotinib discontinuation/completion, n (%) | ||||
| None | 81 (38.2) | 49 (35.8) | 32 (43.8) | 0.4258 |
| Surgery | 2 (0.5) | 1 (0.7) | — | 0.9455 |
| Radiotherapy | 38 (17.9) | 21 (15.3) | 17 (23.3) | 0.4884 |
| Chemotherapy | 75 (35.4) | 58 (42.3) | 17 (23.3) | 0.3274 |
| Other alk inhibitor in a clinical trial | 10 (4.7) | 5 (3.6) | 5 (6.8) | 0.3100 |
| Targeted therapy | 21 (9.9) | 16 (11.7) | 5 (6.8) | 0.4748 |
| Other | 2 (0.5) | 1 (0.7) | 2 (2.7) | 0.2252 |
SD = standard deviation; alk = anaplastic lymphoma kinase; nsclc = non-small cell lung cancer.
a
Line of crizotinib initiation was unknown for 2 patients.
b
“At diagnosis” refers, more specifically, to at diagnosis of metastatic alk+ nsclc.